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Abstract
Introduction: We sought to determine whether protocol biopsies 
could be used to guide treatment and improve outcomes in simul-
taneous pancreas-kidney (SPK) patients.
Methods: Between 2004 and 2013, protocol biopsies were per-
formed on SPK patients at 3–6 months and one year post-transplant. 
Maintenance immunosuppression consisted of a calcineurin inhib-
itor, anti-proliferative agent, and corticosteroid. Corticosteroid was 
withdrawn in negative early biopsies, maintained in subclinical/
borderline biopsies, and increased if Banff IB or greater rejection 
was identified. Endpoints included presence of interstitial fibrosis 
and tubular atrophy on biopsy at one year (IF/TA), rejection epi-
sodes, and renal and pancreas function at five years’ followup.
Results: Forty-one SPK transplant patients were reviewed and a 
total of 75 protocol biopsies were identified. On early biopsy, 
51% had negative biopsies, 44% had borderline rejection, and 5% 
had subclinical rejection. Renal and pancreas function were not 
significantly different at one, two, and five years post-transplant 
between negative vs. borderline early biopsy patients. No differ-
ence in the degree of IF/TA was found between these two groups. 
Conclusions: To our knowledge, this is the first study to evaluate 
protocol biopsies as an investigative tool prior to steroid withdrawal 
in SPK patients. Our study suggests that there are no detrimen-
tal functional or histological effects at five years post-transplant, 
despite weaning steroids in the negative biopsy group. 
Introduction 
Interstitial fibrosis and tubular atrophy (IF/TA) is the principle 
cause of kidney allograft failure and is commonly precipi-
tated by episodes of acute rejection.1 While recent improve-
ments in immunosuppressive therapy have reduced the inci-
dence of acute rejection, these pharmacological advances 
have not translated into a reduction in the prevalence of IF/
TA or an improvement in long-term outcomes.2,3 Current 
literature suggests that clinically undetectable graft path-
ology (including borderline and subclinical rejection) may 
be a predictor of future development of IF/TA and eventual 
graft loss.3-5
Subclinical rejection refers to a histological finding of 
acute cellular rejection using the Banff criteria (≥grade IA) 
in the absence of renal dysfunction.3,6 Borderline rejection is 
defined as Banff grade <IA in the absence of renal dysfunc-
tion. While some authors consider borderline rejection to 
be grouped with subclinical rejection, the significance of 
borderline rejection is largely unknown.3
Protocol biopsies are histological allograft samples taken 
at predetermined times after transplant, in the absence of 
any clinically detectable graft dysfunction. These biopsies 
provide the opportunity to recognize silent graft pathology 
(subclinical/borderline changes) in a timely manner and 
potentially optimize treatment to prolong graft function 
and survival. A study by Nankivell et al demonstrated a 
high incidence of IF/TA in simultaneous pancreas-kidney 
(SPK) patients undergoing protocol biopsies.1 However, 
these biopsies were not used to guide subsequent treat-
ment of patients. 
Steroid withdrawal has been controversial in SPK patients, 
as more antiquated studies suggest that rejection rates and 
renal function are potentially impacted if steroids are with-
drawn in all patients irrespective of rejection risk.7 In our 
cohort of SPK patients, we aimed to wean corticosteroids 
in patients with an absence of subclinical or borderline 
rejection at three months in order to reduce steroid-related 
complications. The overall aim of this study was to deter-
mine whether identification of subclinical pathology with 
protocol biopsies could be used to select SPK patients for 
safe steroid withdrawal. 
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Methods
Patients
The institutional review board approved our study. The study 
group consisted of 61 consecutive SPK transplant recipi-
ents. All recipient surgeries occurred at the London Health 
Sciences Centre (LHSC) between January 2004 and August 
2013. Biopsies were read at LHSC by the pathology depart-
ment. Patients were followed for a minimum of five years 
post-transplant. Protocol biopsies were performed on all SPK 
patients at 3–6 months. Exclusion criteria included: 1) patient 
declining protocol biopsy (four patients); 2) patient non-com-
pliance (four patients); 3) early graft loss (seven patients); and 
4) postoperative anticoagulation therapy (five patients). 
Immunotherapy
All SPK patients received anti-thymocyte globulin (total 
5–8 mg/kg) for induction immunosuppression and con-
tinued on three-drug maintenance immunosuppression 
(combination of calcineurin inhibitor [tacrolimus], anti-
proliferative agent [mycophenolate mofetil or sirolimus], 
and corticosteroid). Target tacrolimus levels were 5–8 
ng/ml in the first three months and 3–5 ng/ml thereafter. 
Methylprednisolone was initiated at 250 mg IV, reduced 
to 1 mg/kg IV, and reduced daily by 10 mg until oral 
prednisone was administered at 5 mg daily. 
Protocol biopsies
The early 3–6-month protocol biopsy determined the deci-
sion to alter corticosteroid therapy. Biopsies were performed 
under ultrasound guidance with a Monopty biopsy gun 
(Bard®, Covington GA, U.S.). The biopsy was adequate if 
a minimum of two full cores with a total of >8 glomeruli 
were available for assessment under microscopy. If there 
was no sign of rejection on the biopsy, the prednisone dose 
was tapered and withdrawn over two weeks. If there was 
borderline rejection on the biopsy, then prednisone therapy 
was maintained at 5 mg daily. If Banff IB or greater rejec-
tion was identified, patients were treated with methylpred-
nisolone boluses (250 mg then 1 mg/kg the next day, with 
reductions of 10 mg daily until a dose of 5 mg daily was 
achieved). Repeat biopsy within nine months was performed 
to determine presence or absence of rejection or IF/TA.
Protocol biopsies were not performed on the pancreas 
graft due to technical difficulties in visualizing the pancreas 
and risk of pancreatitis or bleeding. As well, assessment of 
post-transplant donor-specific antibodies was not performed 
in our patients and is currently not part of our post-transplant 
monitoring protocol.
Outcomes
The outcomes measured included creatinine, estimated 
glomerular filtration rate (eGFR), presence of IF/TA, number 
of rejection episodes, and HbA1c. 
Statistics
Statistical analysis was carried out using GraphPad Prism 
6.0 software (GraphPad Software, Inc. La Jolla, CA, U.S.). 
T-test was used for the comparison of means and standard 
deviations of the two groups. Log-rank (Mantel-Cox) test was 
used to compare graft and patient survival. Analysis was 
intention to treat based on their initial early protocol biopsy. 
Differences were considered significant when p<0.05.
Results 
Patients and graft survival
Forty-one consecutive SPK transplant patients were reviewed. 
Donor and recipient characteristics were similar between the 
steroid withdrawal group (no rejection on protocol biopsy) 
and the group maintained on steroids (borderline or acute 
rejection). Demographics are displayed in Tables 1 and 2. 
The five-year death-censored renal graft survival rate was 
95% in the steroid withdrawal and 100% in the maintenance 
group (p=NS). The graft losses were secondary to infections 
and non-compliance. The five-year death-censored pancreas 
graft survival rates were identical at 85% in each group. 
Graft losses were secondary to non-compliance and infec-
tions, as well as to the development of post-transplant dia-
betes mellitus from obesity. 
Rejection
A total of 41 early protocol biopsies were performed in 41 
patients between three and six months. Twenty-six out of 41 
patients had one-year followup protocol biopsies that were 
adequate for analysis; 12 of 41 patients had 16 additional 
protocol biopsies beyond the followup biopsy. Overall, a 
total of 85 protocol biopsies were performed. In addition 
to protocol biopsies, 24 of 41 patients underwent for-cause 
biopsies for allograft dysfunction at some point during the 
five years of followup. 
Fifty-one percent of patients had no histological chan-
ges on early protocol biopsy (negative biopsy group) and 
prednisone therapy was withdrawn. The one-year protocol 
biopsy of these patients (n=14) showed that 57% remained 
negative, 36% developed borderline rejection, and 7% 
developed Banff IB rejection. Patients who later developed 
borderline rejection were restarted on steroid therapy. Forty-
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four percent of patients had borderline changes on early 
protocol biopsy (borderline biopsy group) and prednisone 
therapy was maintained. The one-year protocol biopsy of 
these patients (n=11) showed that 36% were negative, 55% 
remained borderline, and 9% developed C4d+/DSA+ sub-
clinical humoral changes (Fig. 1). 
Of note, IFTA was quantified using the Banff classifica-
tion. Grade I represented mild IF/TA and Grade II repre-
sented moderate IF/TA. There was only one case of Grade 
II IF/TA on protocol biopsy. The remaining protocol biopsies 
were Grade I IF/TA. 
There was no difference in the percentage of IF/TA 
between the negative vs. borderline biopsy groups at one 
year (56% vs. 50%; p=0.81) or at any protocol biopsy time 
point (67% vs. 67%; p=1). There was also no difference in 
the number of clinical rejection episodes in the five years of 
followup between the two groups (17% vs. 25%; p=0.62).
Two early protocol biopsies (5%) demonstrated subclinic-
al rejection (Banff IA). The first patient received prednisone 
maintenance successfully, but refused any further protocol 
biopsy and had excellent renal and pancreatic graft function 
at five years. The second patient had a biopsy demonstrating 
Banff IA rejection. He was successfully treated with predni-
sone bolus therapy. He later developed Banff IIA rejection 
with C4d+/DSA+ antibody-mediated rejection at 18 months, 
demonstrated on followup protocol biopsy, despite having 
excellent graft function (creatinine 105 µmol/L, HbA1c 
0.056). He was treated with plasmapheresis/intravenous 
immunoglobulin 2 g/kg and prednisone therapy, but lost 
his renal allograft from ongoing rejection four years post-
transplant. He remains insulin-independent. One patient in 
the borderline group had a rising amylase despite having a 
stable serum creatinine at nine months postoperatively. This 
patient had a negative renal biopsy, but since the amylase 
remained elevated, the pancreas was biopsied one week 
later; this showed no evidence of rejection. 
Four patients were excluded from the study because they 
declined the early protocol biopsy. Three of these patients 
received a biopsy at one year, which showed borderline 
changes. One of these patients subsequently developed anti-
body-mediated rejection at six months. The fourth patient 
never received any protocol biopsies. He later developed 
IF/TA, demonstrated on a for-cause biopsy at 11 months. 
Graft function and survival
The three-month (89 vs. 105 µmol/L; p=0.05) and two-year 
(90 vs. 105 µmol/L; p=0.04) post-transplant serum creatinine 
was statistically lower in the negative vs. borderline biop-
sy group (Table 3). However, the five-year post-transplant 
serum creatinine was not significantly different between 
the two groups. More importantly, there was no difference 
in the eGFR, as calculated by the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation between 
the two groups at three months (90 vs. 80 ml/min/1.72 m2; 
p = 0.21), one year (75 vs. 76 ml/min/1.72 m2; p=0.85), two 
Table 1. Donor demographics
Characteristic
Negative biopsy 
(steroid withdrawal)
Positive biopsy 
(steroid maintained)
p
Age 31.8±12.3 29.4±10.7 NS
Kidney CIT 5.78±2.47 6.96±2.58 NS
Pancreas CIT 6.47±2.60 8.13±3.06 NS
BMI (kg/m2) 25.85±2.99 25.6±4.2 NS
Data are mean ± standard deviation. BMI: body mass index; CIT: cold ischemic time.
Table 2. Recipient demographics
Characteristic
Negative biopsy 
(steroid 
withdrawal)
Positive biopsy 
(steroid 
maintained)
p
Age 43.8±8.70 41.9±9.13 NS
Sex (male %) 55% 65% NS
Race (caucasian %) 95% 100%
Transplant number 
(first %)
100% 100%
PRA % 0.7±2.8 1.2±3.4 NS
Dialysis (% HD) 60% 71% NS
Data are mean ± standard deviation. HD: preoperative mode of dialysis = hemodialysis; 
PRA%: % panel reactive antibody.
Total early protocol
biopsies (n=26)
Borderline (n=12)
46%
Steroid maintained
1-year protocol
biopsy (n=10)
Negative (n=12)
46%
Steroid withdrawn
1-year protocol
biopsy (n=9)
Negative (n=5)
56%
Borderline (n=3)
33%
Banff 1B (n=1)
11%
Subclinical (n=2)
8%
Steroid bolus
1-year protocol
biopsy
Borderline
(n=1)a
Negative (n=4)
40%
Borderline (n=5)
50%
C4d+/DSA+
(n=1)
10%
Fig. 1. Early protocol biopsy results. Twenty patients had one-year followup 
protocol biopsies that were adequate for analysis. aPatients later developed  
antibody-mediated rejection at 18 months.
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years (82 vs. 75 ml/min/1.72 m2; p=0.53), andfive years (65 
vs. 55 ml/min/1.72 m2; p=0.91) post-transplant. The five-
year kidney graft survival was 95% and 100% in the negative 
and borderline biopsy groups, respectively (p=NS). 
In terms of pancreatic transplant function, both groups 
displayed similar HbA1c levels at three month (0.053 vs. 
0.056; p=NS), one year (0.053 vs. 0.058; p=0.05), and five 
years (0.053 vs. 0.048; p=NS) post-transplant. The percent-
age of patients who remained insulin-free was the same in 
both groups at five years (Table 4). 
Steroid-related complications 
We did not detect a difference in common steroid-related 
complications, including impaired glucose tolerance, hyper-
tension, and dyslipidemia, between the negative and border-
line biopsy groups (Table 5). As well, none of the patients 
developed avascular necrosis of the hips and four patients 
in each group had cataract surgeries in the five years fol-
lowing transplantation. 
Discussion
In this study, 44% of patients had early protocol biopsies 
demonstrating borderline rejection and 5% had subclinical 
rejection. These results are consistent with the findings of 
Nankivell et al, who demonstrated subclinical rejection 
(acute and borderline) in 45.7% of patients at three months.1
In addition, our protocol biopsies demonstrated a high per-
centage of IF/TA at one year. The ability to detect subclinical 
rejection and IF/TA in kidney-only transplant patients had 
previously been shown to allow early treatment that may 
theoretically prolong graft function and survival.6,8 Choi et 
al demonstrated that subclinical rejection detected at two 
weeks post-transplant was associated with a 30% decrease 
in graft survival at 10 years compared to those with normal 
findings.8 A small, randomized control trial by Rush et al 
showed that treatment of subclinical rejection detected by 
protocol biopsies lead to better histological and functional 
outcomes in renal transplant patients compared to patients 
with no protocol biopsies.6 Recent findings from Loupy et al 
showed that there are two distinct phenotypes of subclinical 
rejection, T cell-mediated rejection (TCMR) and antibody-
mediated rejection (ABMR), which are associated with dis-
tinct outcomes.9 Specifically, subclinical ABMR detected on 
one-year protocol biopsy was associated with the poorest 
graft survival compared to the subclinical TCMR or negative 
biopsy groups.9 The distinction of subclinical TCMR and 
ABMR was not within the scope of our study. 
The use of corticosteroids is an integral part of immuno-
suppressive therapy, but is also associated with multiple 
adverse effects, including bone demineralization, weight 
gain, impaired glucose tolerance, and heart disease.10
Therefore, steroid withdrawal is a worthwhile goal in the 
management of SPK patients post-transplant. However, his-
torical publications have indicated that steroid withdrawal 
may increase rejection and inferior long-term survival in 
renal transplant recipients.7 In our study, the early proto-
col biopsy was used to determine whether steroid therapy 
could be withdrawn in those patients at low risk for sub-
sequent acute/chronic rejection. We assumed that patients 
with a negative early protocol biopsy represented a “low-
risk” population. In these patients, steroid withdrawal did 
Table 3. Renal function and survival for negative and 
borderline early protocol biopsies
Negative 
(steroid 
withdrawal)
Positive 
(steroid 
maintained)
p
Mean Cr 3 months 89±16 105±30 0.05
1 year 97±17 107±20 0.04
2 years 90±14 105±29 0.04
5 years 92±14 113±15 0.01
Mean eGFR 3 months 90±21 80±20 NS
1 year 75±16 76±15 NS
2 years 82±22 75±18 NS
5 years 65±9 55±18 NS
5-years graft survival 95% 100% NS
Data are means ± standard deviation. CR: creatinine; eGRR: estimated glomerular filtration 
rate; NS: non-significant.
Table 4. Pancreas function and survival for negative and 
borderline early protocol biopsies
Negative 
(steroid 
withdrawal)
Borderline 
(steroid 
maintained)
p
Mean HbA1c 3 months 0.053±0.009 0.056±0.008 NS
1 year 0.052±0.005 0.058±0.009 0.05
5 years 0.053±0.006 0.048±0.004 NS
5-year graft survival 85% 85% NS
Data are means ± standard deviation. Pancreas graft survival is indicated by recipients 
being insulin-free. HbA1c: hemoglobin A1c; NS: non-significant.
Table 5. Steroid-related complications for negative and 
borderline early protocol biopsies 
LDL pre-transplant 
(mmol/L)
LDL 1 year 
post-transplant
p
Negative 
(steroid withdrawal)
1.9±0.5 2.1±0.6 NS
Positive 
(steroid maintained)
1.7±0.6 2.0±0.6 NS
 Blood pressure 
pre-transplant 
(mmHg)
Blood pressure 
post-transplant 
(mmHg)
Negative 
(steroid withdrawal)
137/77 131/72 NS
Borderline 
(steroid maintained)
128/69 130/76 NS
LDL: low- density lipoprotein; NS: non-significant.
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not lead to increased histopathological changes at one year 
compared to borderline/subclinical biopsy patients who 
were maintained on steroids. There was also no difference 
in the eGFR or HbA1c between the two groups at five years 
post-transplant. This suggests that there are no functional 
detrimental effects despite weaning steroids in the nega-
tive early biopsy group. Therefore, the early protocol biopsy 
identified a group in whom steroid therapy could be suc-
cessfully weaned. Compared with early steroid withdrawal 
(within one week) in all patients, minimal steroid exposure 
is not achieved using our approach, which may have limited 
our ability to reduce all steroid-related complications. Our 
biopsy approach, therefore, offers a compromise between 
early withdrawal and steroid maintenance strategies. 
Unlike subclinical rejection, in which treatment is gener-
ally supported, the clinical benefit of treating borderline rejec-
tion is less clear. Roberts et al reported that early biopsy show-
ing borderline changes go on to develop clinical rejection 
if left untreated.11 Nankivell et al showed that patients with 
borderline rejection had subsequent biopsies showing higher 
grades of chronic rejection.1 Herein, we did not detect a dif-
ference between the negative vs. borderline biopsy groups in 
the number of patients with IF/TA at one year and the number 
of clinical rejection episodes at five years post-transplant. This 
finding suggests that low-dose prednisone may be beneficial 
in preventing worsening of IF/TA in the borderline rejection 
group. Greater numbers are needed to determine whether 
modification of immunotherapy (steroid boluses, increasing 
immunotherapy dose) of this “at-risk” group will reduce IF/
TA and improve long-term graft survival. 
In our protocol biopsies, only the kidney transplant is 
biopsied. Our steroid withdrawal protocol assumes that 
concordant rejections occur within both kidney and pan-
creatic allografts. However, it is believed that there may 
be a significant discordance between renal biopsies and 
pancreatic allograft biopsies with regards to the detection 
of rejection.12 As the clinical impact of protocol biopsies of 
the pancreas transplant has not been studied, it is unknown 
whether discordance in subclinical rejections can also occur 
in pancreas and kidney allografts. 
There are a few limitations to this study. First, this was a 
retrospective chart review and patients were not random-
ized to steroid withdrawal vs. maintaining steroid therapy in 
either group. Therefore, the true significance of steroid with-
drawal on renal function and histology of biopsy-negative 
patients is unknown, and potentially, the rates of IF/TA could 
have been reduced if corticosteroids were not withdrawn 
on the biopsy-negative group. Importantly, the number of 
patients included in this study was small, and the impact of 
steroid withdrawal on steroid-related factors was beyond the 
scope of the study. These weaknesses were balanced by the 
long followup of a minimum of five years in our cohorts. We 
recommend a study using greater patient numbers in order 
to determine the optimal approach in treating borderline 
rejection discovered on protocol biopsy in SPK patients.
Conclusion 
To our knowledge, this is the first study to evaluate the role 
of protocol biopsies in guiding steroid withdrawal for SPK 
transplant patients. Our study suggests weaning steroids in the 
negative early biopsy group does not lead to worse functional 
or histological pathology at five years post-transplant vs. the 
borderline group. Further investigations are needed to deter-
mine the significance of borderline rejection and whether 
immunotherapeutic modifications have any impact on IF/TA. 
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